BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData

BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials

Shilpa Medicare lunches pemetrexed injection in India under the brand name VRTU

Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India

Biostar Pharma receives FDA approval Utidelone Injectable Phase 2/3 clinical trial for cell lung cancer

This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable

Indica Labs and Lunit enters into alliance for digital pathology AI workflows

Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution

Patritumab Deruxtecan shows better clinical activity in patient with lung and breast cancer

Subgroup analysis by HER2 expression from phase 1/2 trial of patients with HER3 expressing metastatic breast cancer highlighted in a second Presidential Session

Alembic gets USFDA final approval for ANDA Docetaxel Injection

Moderna and Merck announce investigational personalized cancer vaccine mRNA-4157/V940

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial

Genome sequencing solutions will help to bring precision in lung cancer therapy, says GlobalData

APAC region contributed around 50% of the in-vitro diagnostics market in 2022

Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers

Positive opinions based on significant survival benefit

Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study

Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer